Amgen watcher

Total Rating:
0 / 0

1 Comment

    • Sun Mar 23rd 01:22 AM | Rating: 0 0
      Commented on:
      Amgen: Valued on Profits, Not Growth
      You keep saying Amgen has a terrible pipeline. What about Denosumab and Vectibix? Denosumab will most likely become a blockbuster if marketed. Vectibix is on its way to 1st and 2nd line cancer treatment, which will boost current sales dramatically.
      View article »
Contribute an Article Become a Seeking Alpha Contributor